🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPrediabetic and scared - will this actually prevent diabetes? — need advice

Prediabetic and scared - will this actually prevent diabetes? — need advice

JessicaH_TX Wed, Feb 18, 2026 at 8:37 AM 21 replies 910 viewsPage 1 of 5
JessicaH_TX
Senior Member
4,123
13,456
Dec 2023
Houston, TX
Feb 18, 2026 at 8:37 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very little. The improvement on this class comes from two directions — direct glucose-dependent insulin secretion and glucagon suppression, plus the indirect effect of weight loss on insulin sensitivity — and the second continues after the first has plateaued.

Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.

What I am after is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner. Numbers rather than impressions, if you have them.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
6 1wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 3 others
Reply Quote Save Share Report
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Feb 18, 2026 at 9:00 AM#2
JessicaH_TX said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 22%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

5 0stefan_berlin, Dr.EM_Chicago, pete_RVA and 2 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Feb 18, 2026 at 9:23 AM#3
JessicaH_TX said:
HbA1c reflects roughly three months of average glycaemia weighted toward the most recent weeks, which is why repeating it at six weeks tells you very…

Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include:

BiomarkerAssociationEvidence Level
Baseline BMIHigher BMI → greater absolute weight lossStrong
Fasting insulinHigher insulin → better responseModerate
GLP1R gene variantsrs6923761 → variable responsePreliminary
Baseline hsCRPHigher CRP → greater CV benefitModerate
Early weight loss (4 wk)≥3% at 4 wks → strong predictor of ≥10% at 68 wksStrong

The 4-week early responder criterion is the most clinically actionable: if you haven't lost ≥3% by week 4 at a therapeutic dose, discuss optimization strategies with your provider.

Last edited: Feb 18, 2026 at 11:23 AM
4 24LibrarianMeg, bri_stats, pete_manc_UK and 1 other
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Feb 18, 2026 at 9:45 AM#4
labquiet_amy said:
Patient selection optimization for glycaemic control: emerging predictive biomarkers for GLP-1 agonist response include: Biomarker Association…

Insulin sensitivity test (HOMA-IR) on glycaemic control — arguably the most important metabolic marker most people aren't tracking:

HOMA-IR = (fasting insulin × fasting glucose) ÷ 405

My numbers: Baseline HOMA-IR = 5.4 (insulin resistant) → Current = 1.4 (insulin sensitive)

Anything above 2.0 indicates insulin resistance. The goal is below 1.5. GLP-1 agonists address the root metabolic dysfunction, not just the symptoms. This is why they work so much better than calorie restriction alone.

3 23NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin
Reply Quote Save Share Report
steph_laguna
Member
234
1,123
Nov 2024
Laguna Beach, CA
Feb 18, 2026 at 11:47 AM#5
mike_nyc said:
Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 22%.

Same experience, arrived at from the opposite direction.

2 22marco_milano, pam_columbus
Reply Quote Save Share Report
1235

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register